Action to Control Cardiovascular Disease Risk in Diabetes Follow-up Study

Acronym: ACCORDION NIDDK Contact: Saul Malozowski Principal Investigator(s): Not Available

ACCORDION (sponsored by NHLBI) is a prospective, observational follow-up study of at least 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.  Treatment in ACCORD ended in 2009 and ACCORDION is designed to further elucidate the long-term effects of the ACCORD treatment strategies and provide additional data on the relationships among various cardiovascular and diabetic risk factors.

Click outside of the light box to close the box.